Guideline Synthesis: Assessment and Management of Attention Deficit Hyperactivity Disorder (ADHD)

February 17, 2011 According to a comparison of guidelines used by the American Academy of Child and Adolescent Psychiatry (AACAP) and the Scottish Intercollegiate Guidelines Network (SIGN), medications should be a primary treatment for children with attention deficit hyperactivity disorder (ADHD) with psychostimulants as the first choice particularly when no comorbidity is present. AACAP recommends dextroamphetamine and methylphenidate; mixed salts amphetamine, and atomoxetine; SIGN recommends the same medications, with the exception of mixed salts amphetamine, are not licensed in the UK. Both emphasized, that if a patient has a robust response to medication and subsequently shows normative functioning in academic . . .